KL
CERO

KIM LLC’s CERo Therapeutics CERO Stock Holding History

KIM LLC’s Portfolio CERO Stock Details CERO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-50
Closed -$1.07M – 463
2023
Q1 		$1.07M Hold
50
– – 0.07% 212
2022
Q4 		$1.03M Hold
50
– – 0.06% 293
2022
Q3 		$1.01M Hold
50
– – 0.05% 361
2022
Q2 		$1M Buy
+50
New +$1M 0.05% 361

Other funds holding CERO

CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
MC
Meteora Capital Boca Raton, Florida $1.21B AUM 13.69% 1-Year Est. Return
MTCM
Mint Tower Capital Management Amsterdam, Netherlands $871M AUM 8.61% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $351M AUM 21.82% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $2.18B AUM 13.58% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Walleye Trading
Walleye Trading New York $87.6B AUM 68.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

KIM LLC's CERO Position: Q2 2023 in Review

KIM LLC sold out of CERo Therapeutics (CERO) in Q2 2023, closing a stake of 50 shares — an estimated $1.07M sold.

KIM LLC first reported a position in CERO in Q2 2022 and held it in 4 quarters. The position peaked at $1.07M in Q1 2023. 12 funds tracked by Wall St. Rank hold CERO as of Q2 2023.

  • KIM LLC reported no remaining CERo Therapeutics position as of Q2 2023 after selling out during the quarter.
  • KIM LLC sold 50 CERo Therapeutics shares in Q2 2023, an estimated $1.07M.
  • KIM LLC first reported a position in CERo Therapeutics in Q2 2022 and held it in 4 quarters.
  • KIM LLC's CERo Therapeutics position peaked at $1.07M in Q1 2023.
  • 12 funds tracked by Wall St. Rank held CERo Therapeutics as of Q2 2023.

Based on KIM LLC's 13F filing for Q2 2023, filed 14 Aug 2023.